Oncotarget · 2015 · 36 citations · 55 references
MedicineHematologyOncologyApoptosisCancer PharmacologyMolecular OncologyApoptosis In CancerApoptosis ModulationApoptosis RegulationApoptosis ResistanceBcl-2 Family ProteinsHematologic Malignancy TherapyAcute Lymphoblastic Leukemia TreatmentApoptosis DysregulationBh3 Mimetic CompoundsMtor InhibitionMtor SignalingMtorc1 SignalingPi3k-akt-mtor SignalingRefractory Acute Lymphoblastic Leukemia
// Stefano Iacovelli 1, * , Maria Rosaria Ricciardi 2, * , Matteo Allegretti 1 , Simone Mirabilii 1 , Roberto Licchetta 2 , Paola Bergamo 1 , Cinzia Rinaldo 3 , Ann Zeuner 4 , Robin Foà 1 , Michele Milella 5 , James A. McCubrey 6 , Alberto M. Martelli 7 , Agostino Tafuri 2 1 Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Italy 2 Hematology, “Sant’Andrea” Hospital - Sapienza University of Rome, Department of Clinical and Molecular Medicine, Rome, Italy 3 Institute of Molecular Biology and Pathology, National Research Council, Rome, Italy 4 Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy 5 Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy 6 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA 7 Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy * These authors have contributed equally to this work Correspondence to: Agostino Tafuri, e-mail: agostino.tafuri@uniroma1.it Keywords: acute lymphoblastic leukemia, targeted therapies, BH3 mimetic resistance, mTOR inhibition, Mcl-1 Received: April 09, 2015 Accepted: September 03, 2015 Published: September 16, 2015 ABSTRACT Several chemo-resistance mechanisms including the Bcl-2 protein family overexpression and constitutive activation of the PI3K/Akt/mTOR signaling have been documented in acute lymphoblastic leukemia (ALL), encouraging targeted approaches to circumvent this clinical problem. Here we analyzed the activity of the BH3 mimetic ABT-737 in ALL, exploring the synergistic effects with the mTOR inhibitor CCI-779 on ABT-737 resistant cells. We showed that a low Mcl-1/Bcl-2 plus Bcl-xL protein ratio determined ABT-737 responsiveness. ABT-737 exposure further decreased Mcl-1, inducing apoptosis on sensitive models and primary samples, while not affecting resistant cells. Co-inhibition of Bcl-2 and the mTOR pathway resulted cytotoxic on ABT-737 resistant models, by downregulating mTORC1 activity and Mcl-1 in a proteasome-independent manner. Although Mcl-1 seemed to be critical, ectopic modulation did not correlate with apoptosis changes. Importantly, dual targeting proved effective on ABT-737 resistant samples, showing additive/synergistic effects. Together, our results show the efficacy of BH3 mimetics as single agent in the majority of the ALL samples and demonstrate that resistance to ABT-737 mostly correlated with Mcl-1 overexpression. Co-targeting of the Bcl-2 protein family and mTOR pathway enhanced drug-induced cytotoxicity by suppressing Mcl-1, providing a novel therapeutic approach to overcome BH3 mimetics resistance in ALL.
55
Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex
Dos D. Sarbassov, David A. Guertin, Siraj M. Ali et al. · Science · 2005 · 6.2K citations
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker et al. · Nature · 2005 · 3.4K citations
Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action
Kenta Hara, Yoshiko Maruki, K. Yoshino et al. · Cell · 2002 · 1.8K citations · Full text